Status:
RECRUITING
A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Conditions:
Primary Membranous Nephropathy
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).
Eligibility Criteria
Inclusion
- Key
- • Diagnosed with pMN with confirmatory historical biopsy. If no historical biopsy was performed that confirmed pMN, a biopsy can be performed during Screening to confirm eligibility
- Key
Exclusion
- • Hypersensitivity to investigational medicinal product or to any of its excipients
- Other protocol defined Inclusion/Exclusion criteria will apply
Key Trial Info
Start Date :
September 30 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 29 2028
Estimated Enrollment :
176 Patients enrolled
Trial Details
Trial ID
NCT07204275
Start Date
September 30 2025
End Date
December 29 2028
Last Update
December 16 2025
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Renal Associates
Montgomery, Alabama, United States, 36117
2
Southwest Kidney Institute, PLC (SKI) - Surprise
Surprise, Arizona, United States, 85374
3
Academic Medical Research Institute (AMRI)
Los Angeles, California, United States, 90022
4
Valiance Clinical Research - Internal Medicine
Tarzana, California, United States, 91356